S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
MarketsFN
Home/Hedge Funds/Baker Bros Advisors/Q2 2020

Baker Bros Advisors

Period: Q2 2020 Β· Filed: 2020-08-14
View on SEC EDGAR β†—
AUM
$22.67B
Total portfolio value
Positions
114
Reported securities
Top Holding
SGENXXXX
35.4% $8.03B
QoQ Changes
+8 / -8
new Β· exited
⚠️13F Filing Disclosure

AUM figures shown are calculated by summing the reported market value of all positions in SEC 13F-HR filings β€” not the fund's actual assets under management.

  • Excludes cash, bonds, private equity, short positions, and foreign-listed stocks not required to be reported.
  • For PUT and CALL options, the reported Value is the notional value of the underlying shares β€” not the option premium paid. This significantly overstates the actual capital at risk.
  • Actual fund AUM is typically higher and includes strategies, instruments, and positions that never appear in a 13F.
  • 13F filings cover institutional managers with β‰₯$100M in 13F securities. Positions reflect end-of-quarter holdings, disclosed up to 45 days after the period ends.

Data sourced from SEC EDGAR. This tracker is for informational purposes only and does not constitute investment advice.

Portfolio Holdings

Top 30 positions

⚠️ Performance % calculated from filing date ( 2020-08-14) shown is the underlying stock price movement β€” not the derivative's P&L.
TickerIssuerNotionalPort %@ FilingNow (EOD)Since FilingAllocation
SGENXXXXSeattle Genetics, Inc.$8.03B35.43%β€”β€”
35.4%
INCYIncyte Corporation$3.33B14.67%$103.97$116.86+12.4%
14.7%
ONCBeiGene, Ltd.$2.22B9.79%$188.40$297.65+58.0%
9.8%
ACADACADIA Pharmaceuticals Inc.$2.03B8.96%$48.47$25.97-46.4%
9.0%
ALXNAlexion Pharmaceuticals, Inc.$983.3M4.34%β€”β€”
4.3%
BMRNBioMarin Pharmaceutical Inc.$936.1M4.13%$123.34$58.99-52.2%
4.1%
KODKodiak Sciences Inc.$626.4M2.76%$54.12$38.54-28.8%
2.8%
ASNDAscendis Pharma A/S$501.4M2.21%$147.90$274.50+85.6%
2.2%
NVTAQInvitae Corporation$359.0M1.58%β€”β€”
1.6%
MYOKMyoKardia, Inc.$305.7M1.35%β€”β€”
1.4%
AMRNXXXXAmarin Corporation plc$238.7M1.05%β€”β€”
1.1%
ARGXargenx SE$229.6M1.01%$225.23$939.68+317.2%
1.0%
IGMSIGM Biosciences, Inc.$229.5M1.01%β€”β€”
1.0%
MDGLMadrigal Pharmaceuticals, Inc.$169.8M0.75%$113.25$528.10+366.3%
0.8%
MRTXMirati Therapeutics, Inc.$161.0M0.71%β€”β€”
0.7%
EXASExact Sciences Corporation$160.5M0.71%β€”β€”
0.7%
NBIXNeurocrine Biosciences, Inc.$110.7M0.49%$122.00$174.26+42.8%
0.5%
PRNBPrincipia Biopharma Inc.$94.5M0.42%β€”β€”
0.4%
FMTXForma Therapeutics Holdings, Inc.$93.0M0.41%β€”β€”
0.4%
CERSCerus Corporation$90.5M0.40%$6.60$3.16-52.1%
0.4%
HRTXHeron Therapeutics, Inc.$88.5M0.39%$14.71$0.44-97.0%
0.4%
INSMInsmed Incorporated$83.3M0.37%$27.54$111.60+305.2%
0.4%
AXSMAxsome Therapeutics, Inc.$83.1M0.37%$82.28$244.31+196.9%
0.4%
ADCTADC Therapeutics SA$79.0M0.35%$46.81$1.19-97.5%
0.3%
BCELAtreca, Inc.$75.2M0.33%β€”β€”
0.3%
KNSAKiniksa Pharmaceuticals, Ltd.$71.3M0.31%$25.48$64.53+153.3%
0.3%
ADAPYAdaptimmune Therapeutics plc$66.8M0.29%$10.01$0.04-99.6%
0.3%
BCRXBioCryst Pharmaceuticals, Inc.$65.6M0.29%$4.76$9.84+106.7%
0.3%
DBVTDBV Technologies S.A.$64.2M0.28%$8.78$15.82+80.2%
0.3%
ZYMEZymeworks Inc.$61.6M0.27%$36.07$26.31-27.1%
0.3%

Quarter-on-Quarter Activity

Q2 2020 vs. Q1 2020

New Positions (8)

TickerIssuerNotionalSince Filing
FMTXForma Therapeutics Holdings, Inc.$93.0M
ADCTADC Therapeutics SA$79.0M-97.5%
ALTAltimmune, Inc.$22.6M
NVAXNovavax, Inc.$20.1M
VXRTVaxart, Inc.$14.5M
XENEXenon Pharmaceuticals Inc.$10.0M
BNRBurning Rock Biotech Limited$6.8M
TARAProtara Therapeutics, Inc.$5.8M

Exited Positions (8)

TickerIssuerNotional
RARXRa Pharmaceuticals, Inc.$100.5M
URGNUroGen Pharma Ltd.$12.0M
BDSIBioDelivery Sciences International, Inc.$6.2M
TARAArTara Therapeutics, Inc.$4.6M
MLNDMillendo Therapeutics, Inc.$4.4M
NERVXXXXMinerva Neurosciences, Inc.$4.1M
HARPXXXXHarpoon Therapeutics, Inc.$2.4M
MNLOMenlo Therapeutics Inc.$1.7M

Increased (8)

TickerIssuerNotionalShares Ξ”
BLUEXXXXbluebird bio, Inc.$14.3M+562.5%
OVIDOvid Therapeutics Inc.$3.2M+559.6%
AUTLAutolus Therapeutics plc$6.8M+209.8%
AGLEAeglea BioTherapeutics, Inc.$32.5M+155.6%
EVFMEvofem Biosciences, Inc.$0.7M+129.4%
ANABAnaptysBio, Inc.$8.2M+119.0%
KRTXKaruna Therapeutics, Inc.$6.1M+95.3%
CRNXCrinetics Pharmaceuticals, Inc.$3.0M+81.6%

Trimmed (8)

TickerIssuerNotionalShares Ξ”
MRKRMarker Therapeutics, Inc.$-2.3M-83.6%
TCDAQTricida, Inc.$-37.0M-70.5%
CPRXCatalyst Pharmaceuticals, Inc.$-1.8M-52.9%
NGMNGM Biopharmaceuticals, Inc.$-0.6M-50.2%
GWPHGW Pharmaceuticals plc$-9.8M-50.1%
ARAVAravive, Inc.$0.0M-49.8%
MTNBMatinas BioPharma Holdings, Inc.$-0.6M-44.2%
IFRXInflarx N.V.$-1.9M-40.5%
← Back to Hedge Funds